Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Ophthalmology
Financial review
Immunology
2023 priorities
Innovation: Clinical trials
Neuroscience
Global Health
CoartemⓇ - PGH-1 (artemisinin combination therapy)
NCT04300309 CALINA (CCOA566B2307)
Malaria, uncomplicated (<5kg patients)
Phase 3
Indication
Phase
Patients
44
Primary
Outcome
Measures
Arms
Intervention
Artemether Cmax
Target
Patients
Experimental: artemether lumefantrine (2.5 mg:30 mg)
artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per
dose
Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium
falciparum malaria
Primary outcome measure: 2023
Readout
Milestone(s)
Publication
TBD
Appendix
Abbreviations
Oncology
Other
Biosimilars
102 Investor Relations | Q4 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation